Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm, Residual 1

Interventions

Specimen Handling 624pembrolizumab 603Magnetic Resonance Spectroscopy 550Carboplatin 444Cisplatin 394Cyclophosphamide 392Biopsy 368Paclitaxel 320Nivolumab 320Gemcitabine 313Radiotherapy 279Bevacizumab 242Dexamethasone 220fludarabine 210Docetaxel 197durvalumab 192Oxaliplatin 184venetoclax 182atezolizumab 182Fluorouracil 174Rituximab 172Pemetrexed 171Capecitabine 167Doxorubicin 164Radiation 162Radiosurgery 156Ipilimumab 143Etoposide 142Leucovorin 140Lenalidomide 136

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × tetrathiomolybdate × 90 days × Clear all
NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Dartmouth-Hitchcock Medical Center

Phase 1/2 Recruiting
204 enrolled
Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡